Trial of novel combined therapy between interferon and hyperlipidemia for chronic hepatitis C patients

Trial of novel combined therapy between interferon and hyperlipidemia for chronic hepatitis C patients - Novel combined therapy for chronic hepatitis C patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005598

Enrollment

100

Registered

2011-05-13

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis type C

Interventions

Group A Fluvastatin(LOCHOL Tablets) 20~30mg/day is administered 12 weeks alone(The example of seriousness administers 60mg in the maximum). Afterwards, administering of using together is done by the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who applies to eligibility criteria for* by chronic hepatitis C ( Serogroup1(genotype1b)and the viral load in blood is HCV-RNA 5.0LogIU/ml or more). *Patient with chronicity C type chronic hepatitis to which treatment resistance is expected by disorder of lipid metabolism(Patient who meets requirement more than one item either the following) 1.Triglyceride value 150mg/dL or more 2.Less than HDL cholesterol value 40mg/dL 3.Area 100cm3 or more of visceral fat 4.The female 25%or more by the body fat percentage man 22% or more.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
SVR rate(HCV RNA lasting negative)	—

Secondary

Measure	Time frame
SBR rate(ALT lasting normalization),the timing HCV RNA negative and adverse event	—

Countries

Japan

Contacts

Public Contactyoshiki murakami

Kyoto University Graduate School of Medicine Center for Genomic Medicine

ymurakami@genome.kyoto-u.ac.jp075-751-4192

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026